Possibilities of Conservative Treatment and Prevention of Cataract Development Using an Anti-cataract Drug

• Published in: Oftalmologii͡a Vol. 21; no. 1; pp. 186 - 192
• Main Authors: Razumovskaya, A. M., Korovyansky, Yu. A., Razumovskiy, E. S.
• Format: Journal Article
• Language: English; Russian
• Published: Ophthalmology Publishing Group 01.04.2024
• Subjects: anti-cataract; cataract; lens; medicine quinax; pathogenesis
• ISSN: 1816-5095; 2500-0845
• DOI: 10.18008/1816-5095-2024-1-186-192

The priority directions of the state policy of the Russian Federation are medical and preventive measures related to the physical and social improvement of the country’s population. These measures are aimed at improving the quality and effectiveness of medical rehabilitation activities and at reducing the morbidity and disability of various groups of patients. Clouding of the lens (cataract) is very different in terms of time of occurrence, localization, flow and is always accompanied by weakening of vision. Existing theories explain the pathogenesis of cataracts by the general state of the body (dysfunction of the glands of internal secretion, hidden tetany, violation of the functions of the autonomic nervous system, main exchange, etc.), unfavorable heredity, negative external influences, etc.The results of various studies strongly show that Quinax (azapentacen 5,12-dihydroazapentacene sodium disulfonate), 0.015 %, is an anticataract agent on all layers of the lens. In 2023, PROFIT-PHARM (PROFIT-PHARM LLC) developed domestic Quinax eye drops. It is necessary to conduct a study of their clinical effectiveness in patients with various types of cataracts, as well as to prevent its occurrence.